Ann: Medical Cannabis Clinical Study Commencing, page-7

TH seems overkill but great news for MXC, real progress

The registration and sale of a pharmaceutical product for the treatment of epilepsy presents a substantial commercial opportunity for MGC Pharmaceuticals. A registered pharmaceutical grade product has the potential to bring relief to millions of epilepsy sufferers across the globe. In Europe alone, there are close to 1 million children and young people with epilepsy and a further 2 million people aged between 20-64 suffering from epilepsy. Each year it is estimated that there are 130,000 new cases of epilepsy among children and adolescents in Europe1.